Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer (vol 76, pg 925, 2015)

被引：0
|
作者：
Bendell, Johanna C. [1 ]
Rosen, Lee S. [2 ]
Mayer, Robert J. [3 ]
Goldman, Jonathan W. [2 ]
Infante, Jeffrey R. [1 ]
Benedetti, Fabio [4 ]
Lin, Donghu [5 ]
Mizuguchi, Hirokazu [4 ]
Zergebel, Christopher [4 ]
Patel, Manish R. [6 ]
机构：
[1] PLLC, Sarah Cannon Res Inst, Tennessee Oncol, 250 25th Ave North,Suite 200, Nashville, TN 37203 USA
[2] Univ Calif, 2020 Santa Monica Blvd,Suite 600, Santa Monica, CA 90404 USA
[3] Dana Farber Canc Inst, 450 Brookline Ave,Dana 1602, Boston, MA 02215 USA
[4] Taiho Oncol Inc, 202 Carnegie Ctr,Suite 100, Princeton, NJ 08540 USA
[5] Taiho Pharmaceut Beijing Co Ltd, 9F-9A3,Hanwei Plaza,7th,Guanghua Rd, Beijing 100004, Peoples R China
[6] Sarah Cannon Res Inst, Florida Canc Specialists, 600 N Cattlemen Rd,Suite 200, Sarasota, FL 34232 USA
来源：
CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2016年 / 77卷 / 02期
关键词：
D O I：
10.1007/s00280-015-2890-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：439 / 439
页数：1
相关论文
共 50 条
  • [1] Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
    Johanna C. Bendell
    Lee S. Rosen
    Robert J. Mayer
    Jonathan W. Goldman
    Jeffrey R. Infante
    Fabio Benedetti
    Donghu Lin
    Hirokazu Mizuguchi
    Christopher Zergebel
    Manish R. Patel
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 925 - 932
  • [2] Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
    Bendell, Johanna C.
    Rosen, Lee S.
    Mayer, Robert J.
    Goldman, Jonathan W.
    Infante, Jeffrey R.
    Benedetti, Fabio
    Lin, Donghu
    Mizuguchi, Hirokazu
    Zergebel, Christopher
    Patel, Manish R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (05) : 925 - 932
  • [3] Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
    Johanna C. Bendell
    Lee S. Rosen
    Robert J. Mayer
    Jonathan W. Goldman
    Jeffrey R. Infante
    Fabio Benedetti
    Donghu Lin
    Hirokazu Mizuguchi
    Christopher Zergebel
    Manish R. Patel
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 439 - 439
  • [4] TAS-102 for metastatic refractory colorectal cancer
    Cleghorn, Sean
    LANCET ONCOLOGY, 2015, 16 (07): : E314 - E314
  • [5] A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer
    Cecchini, Michael
    Kortmansky, Jeremy S.
    Cui, Can
    Wei, Wei
    Thumar, Jaykumar Ranchobdhai
    Uboha, Nataliya, V
    Hafez, Navid
    Lacy, Jill
    Fischbach, Neal A.
    Sabbath, Kert D.
    Gomez, Christina M.
    Sporn, Jonathan Reed
    Stein, Stacey
    Hochster, Howard S.
    CANCER, 2021, 127 (09) : 1417 - 1424
  • [6] Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
    Mayer, Robert J.
    Van Cutsem, Eric
    Falcone, Alfredo
    Yoshino, Takayuki
    Garcia-Carbonero, Rocio
    Mizunuma, Nobuyuki
    Yamazaki, Kentaro
    Shimada, Yasuhiro
    Tabernero, Josep
    Komatsu, Yoshito
    Sobrero, Alberto
    Boucher, Eveline
    Peeters, Marc
    Tran, Ben
    Lenz, Heinz-Josef
    Zaniboni, Alberto
    Hochster, Howard
    Cleary, James M.
    Prenen, Hans
    Benedetti, Fabio
    Mizuguchi, Hirokazu
    Makris, Lukas
    Ito, Masanobu
    Ohtsu, Atsushi
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (20): : 1909 - 1919
  • [7] TAS-102 in metastatic colorectal cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2018, 19 (01): : E18 - E18
  • [8] Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study
    Conti, Matteo
    Bolzacchini, Elena
    Luchena, Giovanna
    Bertu', Lorenza
    Tagliabue, Paola
    Aglione, Stefania
    Ardizzoia, Antonio
    Arnoffi, Jessica
    Guida, Francesco Maria
    Bertolini, Alessandro
    Pastorini, Alessandro
    Duro, Maria
    Bettega, Donato
    Roda', Giovambattista
    Artale, Salvatore
    Squizzato, Alessandro
    Giordano, Monica
    CANCERS, 2023, 15 (13)
  • [9] Treatment of TAS-102 in patients with metastatic colorectal cancer
    Ota, Takayo
    Tsukuda, Hiroshi
    Hasegawa, Yoshikazu
    Miyatake, Nozomi
    Suzumura, Tomohiro
    Fukuoka, Masahiro
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).
    Cecchini, Michael
    Kortmansky, Jeremy S.
    Lacy, Jill
    Fischbach, Neal A.
    Thumar, Jaykumar Ranchodbhai
    Sabbath, Kert D.
    Gomez, Christina M.
    Sporn, Jonathan
    Stein, Stacey
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345